| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7348317 | GALDERMA LABS LP | Aqueous compositions containing metronidazole |
Feb, 2022
(2 years ago) | |
| US6881726 | GALDERMA LABS LP | Aqueous compositions containing metronidazole |
Feb, 2022
(2 years ago) | |
Metrogel is owned by Galderma Labs Lp.
Metrogel contains Metronidazole.
Metrogel has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Metrogel are:
- US7348317
- US6881726
Metrogel was authorised for market use on 30 June, 2005.
Metrogel is available in gel;topical dosage forms.
Metrogel can be used as once a day topical treatment of the inflammatory lesions of rosacea.
The generics of Metrogel are possible to be released after 21 February, 2022.
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 30 June, 2005
Treatment: Once a day topical treatment of the inflammatory lesions of rosacea
Dosage: GEL;TOPICAL
How can I launch a generic of METROGEL before it's drug patent expiration?
More Information on Dosage
METROGEL family patents
